Wegovy’s heart benefits due to more than weight loss, Novo says

wegovy’s-heart-benefits-due-to-more-than-weight-loss,-novo-says
Wegovy’s heart benefits due to more than weight loss, Novo says

Novo Nordisk has revealed that the heart protective benefits of its obesity treatment, Wegovy, are not solely due to weight loss. New data presented at a medical meeting suggests that the drug has additional positive effects beyond weight reduction. The study, which was conducted on overweight and obese patients with preexisting heart disease, showed that Wegovy reduced the risk of heart attack, stroke, and heart-related death compared to a placebo. Importantly, these cardiovascular benefits appeared before patients started losing weight, indicating that weight loss alone is not responsible for the heart protection provided by Wegovy.

The trial did not investigate how Wegovy prevents heart disease from occurring, but rather focused on its ability to prevent the condition from worsening. Despite this limitation, the large patient population covered by the trial should prompt doctors to consider prescribing Wegovy to patients with a history of heart attack or obstructive coronary disease and a body mass index over 27. Dr. Bruno Halpern, head of the obesity center at Hospital 9 de Julho in São Paulo, Brazil, even suggested that Wegovy should be a frontline treatment for heart disease.

While the exact mechanisms behind Wegovy’s cardiovascular protection are still speculative, the study researchers noted a consistent effect on associated risk factors such as inflammation, blood pressure, and blood sugar control. These factors are known to impact heart health. Patients on Wegovy experienced decreases in C-reactive proteins, an indicator of inflammation, similar to those seen with cholesterol-lowering statins. Martin Lange, Novo Nordisk’s head of development, emphasized that the cardiovascular benefits of Wegovy are a combination of various factors, including glycemic control, weight loss, and inflammation.

In terms of safety, the study showed that Wegovy was well-tolerated, with adverse side effects primarily related to gastrointestinal disorders like nausea and vomiting. However, nearly 1,500 patients discontinued Wegovy treatment due to these side effects, compared to 718 patients in the placebo group. It is worth noting that participants in the heart study were not required to track their diet and exercise, unlike in obesity trials.

The study’s results may not be applicable to all GLP1-class drugs and could be specific to semaglutide, the active ingredient in Wegovy. Analyst Emily Field from Barclays highlighted this uncertainty. Novo Nordisk expects to update Wegovy’s label to include the heart benefits, with approval anticipated in the U.S. and EU next year.

In related news, Eli Lilly’s weight-loss treatment, previously marketed as Mounjaro for diabetes, was recently approved by U.S. and UK drug regulators.

About News Team

Hi, I'm Alex Perez, an experienced writer with a focus on lifestyle and culture news. From food and fashion to travel and entertainment, I love exploring the latest trends and sharing my insights with readers. I also have a strong interest in world news and business, and enjoy covering breaking stories and events.

Have a tip we should know? tips@rhd.news

Most Read

  1. News
    Pandora Papers Financial Leak Shows Us the Secrets of the World’s Rich and Powerful
    3 years ago
  2. Health
    US Supreme Court Rejects J & J TALC Cancer Case Appeal
    3 years ago
  3. Lifestyle
    9 Habits that Drain your Daily Focus and How to Avoid Them
    3 years ago
  4. BUSINESS
    Women’s Demand for Shapewear – the big Trends
    3 years ago
  5. BUSINESS
    Valentino Launches its Cosmetics Line
    3 years ago
  6. Health
    US Promises to Share 60 million Doses of AstraZeneca Vaccines
    3 years ago
  7. Health
    UK Offers Aid Amid Surging COVID-19 Cases in India
    3 years ago
  8. Sports
    Thousands of fans welcome Charlton funeral cortege at Old Trafford
    8 months ago
  9. News
    Brit left fighting for life after train derails in Argentinia
    8 months ago
  10. BUSINESS
    Dubai faces down airline rivals with $50 bln jet orders
    8 months ago
  11. Sunak
    UK’s Sunak brings back Cameron, sacks Braverman
    8 months ago
  12. Sports
    Man United’s Hojlund, Eriksen withdrawn from Denmark team duty
    8 months ago
  13. Health
    Autumn Sneezing Syndrome is on the rise… here’s what you can do
    8 months ago
  14. Canada
    Canada beat Italy to win Billie Jean King Cup for first time
    8 months ago

Follow @rushhourdaily: